Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LG anti-LILRB1
- Development stage
- Unknown
- Lead developer
- LG Chem
- Modality
- Antibody-Based Therapeutics
01
Overview
LG anti-LILRB1: sourced facts only. name: "Preclinical characterization of LG anti-LILRB1, a potent antagonist targeting LILRB1" [DOI:10.1158/1538-7445.am2025-3415]; target: "Preclinical characterization of LG anti-LILRB1, a potent antagonist targeting LILRB1" [DOI:10.1158/1538-7445.am2025-3415]; developer: "LG Chem, Seoul, Republic of Korea." [DOI:10.1158/1538-7445.am2025-3415]; modality: "The protein-based and cell-based binding affinity of anti-LILRB1 antibody was measured using SPR and FACS analysis." [DOI:10.1158/1538-7445.am2025-3415]; stage: "Importantly, the anti-LILRB1 antibody showed tumor growth inhibition in syngeneic model of human LILRB1 transgenic mice with MC38-HLA-G tumor." [DOI:10.1158/1538-7445.am2025-3415]
02
Targets
LILRB1 (Leukocyte immunoglobulin-like receptor subfamily B member 1)
Beyond the preview
Go deeper on LG anti-LILRB1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LG anti-LILRB1.